Cillóniz C, Dominedò C, Garcia-Vidal C, Torres A
Professor Antoni Torres, Pulmonology Department, Hospital Clinic de Barcelona [Hospital Clinic of Barcelona] C/ Villarroel 170, 08036 Barcelona, Spain.
Rev Esp Quimioter. 2019 Sep;32 Suppl 3(Suppl 3):17-23.
Ceftobiprole is a fifth-generation cephalosporin with potent antimicrobial activity against Gram positive and Gram-negative bacteria. It has been approved in major European countries for the treatment of community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP), excluding ventilator-associated pneumonia (VAP). Ceftobiprole is currently in a phase 3 clinical program for registration in the U.S. In 2015, it was designated as an infectious disease product qualified for the treatment of lung and skin infections by the FDA. The efficacy of ceftobiprole in pneumonia has been demonstrated in two-phase III clinical trials conducted in patients with CAP and HAP. The recommended dose in the adult with pneumonia is 500 mg every 8 h infused in 2 h; in case of renal failure, the regimen of administration must be adjusted according to the patient's renal function. It is not necessary to adjust the dose according to gender, age, body weight or liver failure. In case of hyperfiltration, an extension to 4 h infusion of the 500mg TID is required.
头孢比普是一种对革兰氏阳性菌和革兰氏阴性菌均具有强大抗菌活性的第五代头孢菌素。它已在欧洲主要国家获批用于治疗社区获得性肺炎（CAP）和医院获得性肺炎（HAP），但不包括呼吸机相关性肺炎（VAP）。头孢比普目前正处于在美国注册的3期临床项目中。2015年，它被美国食品药品监督管理局指定为有资格用于治疗肺部和皮肤感染的传染病产品。头孢比普在肺炎治疗中的疗效已在两项针对CAP和HAP患者进行的III期临床试验中得到证实。成人肺炎的推荐剂量为每8小时500毫克，在2小时内输注；如果出现肾衰竭，给药方案必须根据患者的肾功能进行调整。无需根据性别、年龄、体重或肝功能衰竭调整剂量。如果出现超滤情况，则需要将500毫克每日三次的输注时间延长至4小时。
